Clinical Trial Update: Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants [Phase 1]

View source ↗

Summary

An early-phase dose-escalation study from Vertex to evaluate the safety and pharmacokinetics of VX-272 in healthy participants, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-272

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: RECRUITING